Frontlight ResearchEarly access
CompletedPhase 4
Effect of Itopride on Semaglutide Gastroparesis
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 60 people enrolled
- Started
- 1 Jan 2026
- Ended
- 30 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Itopride HCI 50 mg
- Placebo
- Record updated
- 25 September 2026
Who can take part
- Age
- 40 years to 60 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- American Society of Anesthesiologists grade I- III
- Age: 40-60 years
- BMI: 20-30 kg/m2
- Diabetic patients on semaglutide (0.5-1mg) SC weekly
- Undergoing elective hysterectomy
Who cannot take part
- history of upper abdominal surgery or the presence of hiatal hernia
- History of allergy to Itopride
- History of cardiac arrhythmia or abnormal ECG
- Neurologic diseases (including Parkinson's disease and multiple sclerosis)
- Hepatic or renal failure
- Other medications inducing gastroparesis (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, and lithium)
- Declining to give written informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery.
Read full original descriptionShow less
The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before anesthesia.
The 2 groups in the trial
- Itopride HCLExisting treatment, for comparison
Daily oral 50mg Itopride tablet TID, 1 hour before meals for 7 days
Treatment: Itopride HCI 50 mg
- PlaceboPlacebo, for comparison
Daily placebo tablet TID, 1 hour before meals for 7 days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Does Itopride Improve Semaglutide Induced Gastroparesis Ultrasound Before Anesthesia? Randomized Controlled Trial
- Record updated
- 25 September 2026